Gilead

Gilead and J&J explore combo HIV Treatment

Wednesday, June 29, 2011 10:00 AM

Gilead and Johnson & Johnson's Tibotec subsidiary are joining forces on a combo HIV treatment, according to FierceBiotech. Under a new pact, Gilead will combine its new boosting agent cobicistat with J&J's Prezista, a protease inhibitor. This new therapy follows a well-traveled development path as drug companies advance new HIV drugs that require fewer pills and offer greater potency.

More... »

Gilead appoints Dr. Muzammil M. Mansuri as SVP, R&D

Thursday, April 28, 2011 12:58 PM

Gilead Sciences, has appointed Muzammil M. (“Muz”) Mansuri, PhD, to senior vice president, research and development strategy and corporate development, a role that expands his current responsibilities to include leadership of corporate development and alliance management.

More... »

Yale and Gilead Sciences announce cancer research collaboration

Wednesday, March 30, 2011 01:40 PM

California-based Gilead Sciences and Yale School of Medicine have announced a research collaboration focused on the discovery of new cancer therapies, according to FierceBiotech.

More... »

Gilead's elvitegravir meets primary endpoint

Tuesday, March 29, 2011 01:04 PM

California-based Gilead Sciences said its phase III clinical trial of investigational antiretroviral agent elvitegravir, an oral integrase inhibitor being evaluated for the treatment of HIV-1 infection in treatment-experienced patients, met its primary objective.

More... »

Cempra expands clinical management team

Friday, March 11, 2011 11:22 AM

Cempra Pharmaceuticals has named David Oldach, M.D., vice president of clinical research. He joins Cempra from Gilead Sciences, where between 2006 and 2011 he helped lead the early clinical development of the company's hepatitis C (HCV) pipeline.

More... »

Gilead Sciences acquires Calistoga Pharmaceuticals

Tuesday, March 1, 2011 08:35 AM

Gilead Sciences made its third major acquisition in the past eight months, buying privately held Calistoga Pharmaceuticals of Seattle for $375 million cash and $225 million in potential milestones.

More... »